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ABSTRACT
Complexes of the HIV transactivation response
element (TAR) RNA with the viral regulatory protein
tat are of special interest due in particular to the
plasticity of the RNA at this binding site and to the
potential for therapeutic targeting of the interaction.
We performed REDOR solid-state NMR experiments
on lyophilized samples of a 29 nt HIV-1 TAR con-
struct to measure conformational changes in the
tat-binding site concomitant with binding of a short
peptide comprising the residues of the tat basic
binding domain. Peptide binding was observed to
produce a nearly 4 A ˚ decrease in the separation
between phosphorothioate and 20F labels incorpor-
ated at A27 in the upper helix and U23 in the bulge,
respectively, consistent with distance changes
observed in previous solution NMR studies, and
with models showing significant rearrangement in
position of bulge residue U23 in the bound-form
RNA. In addition to providing long-range constraints
on free TAR and the TAR–tat complex, these results
suggest that in RNAs known to undergo large
deformations upon ligand binding,
31P–
19F REDOR
measurements can also serve as an assay for com-
plex formation in solid-state samples. To our know-
ledge, these experiments provide the first example
of a solid-state NMR distance measurement in an
RNA–peptide complex.
INTRODUCTION
Characterization of RNA structure and dynamics is critical to
understanding interactions of RNA with regulatory proteins
andwithpotentialRNA-targetedligandmolecules.Elucidation
of the mechanisms and speciﬁcity of complex formation
entails determination of the range of motions and confor-
mations sampled by the RNA en route to the bound state (1).
However, in certain RNA systems, experimental limitations
or sample difﬁculties have thus far precluded acquisition of
key information about the complexes. The interaction of the
HIV-1 transactivation response element (TAR) RNA with the
viral regulatory protein tat is an example of this: although
binding of tat to this RNA motifhas been shown to be essential
for viral replication, and a wide array of biophysical and bio-
chemical techniques have consequently been applied to the
description of the structure (2–7) and motions (8–13) of both
free- and tat-bound TAR, much remains to be learned about
the interaction [for reviews see (14,15)]. Owing to difﬁculties
in preparing properly folded tat protein or suitable samples of
protein–TAR complex, solution NMR and X-ray investiga-
tions to date have studied simpliﬁed models of this system.
Whilethese studies have produced high-resolution RNA struc-
tures for complexes of HIV-2 TAR with argininimide (5), and
of HIV-1 TAR with tat peptides (2,3,6), argininimide (2,3) and
a variety of small molecules (16–19), peptide motion has thus
far precluded the determination of high-resolution structures
for bound peptides or a peptide–HIV-1 TAR complex, and the
contacts tat makes with the TAR-binding site have not been
directly observed.
Well-established solid-state NMR (SSNMR) techniques are
readily available to address many of the aspects of this inter-
action that are not tractable by other means. SSNMR methods
can provide long-range constraints in TAR and determine the
conformation of bound peptides and can study motions on a
wide range of timescales. Use of such experiments, however,
necessitates parallel experiments to conﬁrm proper formation
of the appropriate RNA–ligand complex. One approach to the
veriﬁcation of complex formation in solid-state samples is to
monitor a conformational change by measuring the distance
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doi:10.1093/nar/gki626between isotopic labels introduced at the binding site. When
labels can be positioned such that binding is known or expec-
ted to result in a large change in the inter-label separation,
observation of predicted changes in this distance following
ligand addition gives evidence of complex formation in the
sample.
Measurement of speciﬁc distance changes of sufﬁcient
magnitude to support claims of complex formation requires
a method that can directly measure long distances (>5A ˚)
between isotopic labels in nucleic acids. The standard
SSNMR technique for heteronuclear distance measurements
is the rotational echo double resonance (REDOR) experiment
[(20,21); for reviews see also (22,23)]. REDOR allows direct
measurement of dipolar couplings between isotopic label
pairs. Rf pulses applied during magic angle sample spinning
(Figure 1) are used to restore the effects of selected dipolar
interactions, dephasing the magnetization of any observed
nuclei coupled to the irradiated spins in proportion to their
respective internuclear separations. Decay in the ratio of this
signal (S) to a reference signal (S0) acquired in the absence of
dephasing pulses is monitored as a function of the number of
applied dephasing pulses (‘dephasing time’), then ﬁt to simu-
lation to allow determination of the dipolar coupling constant
and the corresponding internuclear distance.
REDOR has been used to make internuclear distance
measurements in structural studies of numerous biological
systems. Recent applications include studies of drug–DNA
and enzyme–nucleotide complexes, illustrating the utility of
the method for investigation of binding interactions of nucleic
acids (24,25).
31P–
19F REDOR has been used to determine
distances of up to 13 A ˚ in nucleic acids (26,27) and up to 16 A ˚
in proteins (28). As distance constraints acquired using
SSNMR experiments, such as REDOR, are frequently longer
than those measurable using high-resolution NMR, SSNMR
studies can also often provide a useful complement to X-ray or
NOE/RDC-based methods of structure determination, aiding
in reﬁnement of global conformation in structures obtained by
these or other methods.
In the present work, we use
31P–
19F REDOR experiments to
measure the change in the distance between
19F and
31P labels
in the binding region of the HIV-1 TAR RNA (Figure 2)
following binding of the tat-derived peptide 47YGRKKR-
RQRRR57. The distance between a 20F label introduced at
bulge residue U23 and a phosphorothioate 50 of A27 was
observed to change signiﬁcantly, from 10.3 A ˚ in the unbound
RNA to 6.6 A ˚ following binding of the peptide. Both distances
are comparable with those obtained previously in solution
NMR-based models of free TAR and the TAR–tat complex,
and are consistent with the presence of intact complex in the
solid-state sample.
MATERIALS AND METHODS
Sample preparation
TAR RNA. The TAR RNA 29mer 50-GGCCAGA
20FUCUG-
(pS)AGCGAAAGCUCUCUGGCC-30 (where pS indicates a
phosphorothioate label) was purchased from Dharmacon
(Lafayette, CO) and deprotected according to the manufac-
turer’s instructions. The sample was checked for homogeneity
using analytical denaturing PAGE and used without further
puriﬁcation. An aliquot of 1.07 mmol of the RNA was dis-
solved in 430 ml buffer (50 mM NaCl, 10 mM sodium caco-
dylate, pH 5.5), then frozen using liquid nitrogen, lyophilized
and transferred to the MAS rotor (ﬁnal composition 10%
NaCl, and 4.7% cacodylate, respectively, by weight upon
lyophilization).
Figure2. ApicalregionofTARRNA,showing29-residueconstructusedinthe
present work. The hexanucleotide upper loop of wild-type TAR has been
replaced with the stable GAAA tetraloop. Label positions within the RNA
areshownasfollows:
20FUindicates20-fluoro-20-deoxyuridine(atbulgeresidue
U23), and the dot between G26 and A27 denotes a phosphorothioate (pS)
linkage.
Figure 1. REDOR pulse sequence used to measure
19F–
31P dipolar couplings.
Initial phosphorus magnetization is produced by cross polarization from
1Ht o
31P. Application of a series of alternating rotor-synchronized fluorine and
phosphorus 180  pulses dephases
31P transverse magnetization, resulting in
a reduced
31P signal. The extent of dephasing observed is determined by the
19F–
31P dipolar couplings. Comparison of this reduced signal with a reference
signal obtained in the absence of the fluorine dephasing pulses allows
the determination of the dipolar coupling, and thereby, direct extraction of
the internuclear separation between
19F and
31P labeled sites.
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was synthesized on an Applied Biosystems 433A peptide
synthesizer using standard fmoc chemistry, then cleaved and
deprotected by stirring in a 95% TFA, 2.5% triisopropylsilane,
2.5% H2O solution for 2.5 h. The resin was ﬁltered off, and the
TFA/product solution reduced to 2 ml under reduced pressure.
The peptide was isolated by precipitation in cold (0 C) tert-
butyl methyl ether and collectedby centrifugation. The sample
was then resuspended in cold tertbutyl methyl ether and
recentrifuged. After three such reprecipitations, the sample
was allowed to dry overnight at room temperature. The crude
peptide was then puriﬁed by reverse-phase high-performance
liquid chromatography using a Rainin Dynamax 25 · 250 mm
preparatory C18 column [40 min linear gradient, from 2 to
50% solvent B (solvent A, 0.1% TFA in H2O; solvent B,
CH3CN) ﬂow rate 10 ml/min], quantitated using UV/vis
(tyrosine e275 = 1405 cm
 1 mol
 1) and characterized using
electrospray MS. TOCSY solution NMR spectra of a sample
of wild-type TAR taken before and after addition the of
the puriﬁed tat peptide produced diagnostic spectral shifts
shown previously to be indicative of complex formation (3)
(data not shown).
Complex formation. The RNA–peptide complex was formed
as follows: the lyophilized TAR sample was re-dissolved in
500 mlsterile ﬁltered H2O.About1.2equivalents (1.284mmol)
of the puriﬁed peptide were dissolved in 500 ml sterile ﬁltered
H2O. Both solutions were incubated at 37 C for 10 min, then
combined by dropwise addition of the peptide solution to the
RNA solution. The mixture was then returned to the heat block
and held at 37 C for 10 min with frequent, gentle vortexing.
An aliquot of 500 mlH 2O was added, and the solution was kept
at 37 C for a further 50 min with continued gentle vortexing.
A small amount of precipitate was observed to form follow-
ing mixing and was retained in the sample. The solution was
allowed to cool to room temperature, then frozen using liquid
nitrogen, lyophilized and returned to the MAS rotor.
NMR spectroscopy
All experiments were performed on a homebuilt spectrometer
at 4.7 Tesla ﬁeld (200 MHz proton Larmor frequency), using a
homebuilt triply-tuned HFP MAS probe. All measurements
were made at room temperature (26 C), with magic angle
spinning at 6493 Hz. Rf ﬁeld strengths were regulated to
within –1%, spinning speed to within –3 Hz and sample tem-
peratures to within –2 C. All REDOR experiments employed
XY-8 phase cycling on both the
31P and the
19F channels
(Figure 1) (29). Custom made 4 mm zirconia rotor barrels
were purchased from O’Keeffe Ceramics. Samples were con-
ﬁned to the middle 10 mm of the 22 mm rotor. Rotor tips and
end caps were prepared in-house.
Unbound RNA sample. Proton Rf ﬁelds were 48 kHz (initial
p/2 pulses) and 94 kHz (CW decoupling). Cross-polarization
employed a linear proton ramp, from 50 to 71 kHz ﬁeld, with a
1.5 ms contact time. Phosphorus and ﬂuorine rf pulse ﬁelds
were 47 and 62 kHz, respectively. A total of 256 points were
acquired, with a dwell time of 25 ms. Two REDOR data sets
were acquired: three REDOR S and S0 data point pairs were
taken at 6.16 ms (5 REDOR cycle) intervals, and two addi-
tional REDOR point pairs were taken at 4.93 ms (4 REDOR
cycle) intervals. Acquisition time in each case was 6.4 ms and
recycle delay was 2 s. The ﬁrst data set consisted of 122880
scans for each REDOR S or S0 data point, recorded in 6144 or
12288 scan blocks, for a total experiment time of 420 h. The
seconddataset consistedof 61 440 scans foreach REDOR data
point, recorded ina single experiment, foratotal time of140 h.
Bound RNA–peptide sample. Proton rf ﬁelds were 47 kHz
(initial p/2 pulses), 51–73 kHz (ramped CP) and 106 kHz
(CW proton decoupling). Phosphorus and ﬂuorine rf pulse
ﬁelds were 47 and 66 kHz. CP contact time, acquired points
and dwell time used were the same as for the unbound sample.
Four REDOR S and S0 data point pairs were taken, at 1.23 ms
(1 REDOR cycle) intervals. (Owing to rapid dephasing, this
experiment was adjusted to collect S and S0 points at the
shorter intervals.) A total of 147456 scans were acquired
for each REDOR S or S0 data point, in 19 individual 4096
to 14336 scan data sets (19–65 h each; total experiment time
672 h), then summed. Acquisition time and recycle delay were
again 6.4 ms and 2 s, respectively. TOCSY spectra of free and
bound TAR RNA were collected at 500 MHz on a Bruker
Avance spectrometer using DIPSI-2 mixing (60 ms) (30). Data
were collected in  12 h on a sample dissolved in 100% D2O.
Chemical shift identiﬁcations were accomplished based on
published values (3,4) and on the characteristic changes that
occur upon complex formation (3). Data were processed using
UXNMR (Bruker) and analyzed with SPARKY (University of
California, San Francisco).
Data processing
Data processing was performed using in-house NMR pro-
cessing software (Gullringen: a computer program for the
estimation of molecular properties from NMR experiments;
T. Karlsson and G. P. Drobny, manuscript in preparation.) All
simulations were performed using SIMPSON (31), with pulse
widths, phases, ﬁeld strengths and spinning speeds corres-
ponding to the experimental NMR parameters described
above. Ideal cross polarization and proton decoupling were
assumed, and relaxation was ignored. Powder averaging for
REDOR dephasing simulations used crystal ﬁle ZCW232 with
10 gamma angles and a maximum time step (maxdt) of 1.0 ms.
Simulations were repeated using rep2000 and ZCW4180, with
100 gamma angles and maxdt 0.5 to check for convergence.
As inclusion of simulated long-distance
31P–
31P homonuclear
dipolar interactions representing couplings of pS A27 to adja-
cent backbone phosphates in the RNA was found to produce
negligible effects on dephasing, these were omitted from sub-
sequent simulations of the REDOR data. Reduced chi-squared
plotswereusedtodeterminebest-ﬁtdistancesanderrorbounds
(90% conﬁdence intervals).
RESULTS AND DISCUSSION
TAR RNA adopts distinct conformations in
the presence and absence of tat
Given its well-established critical role in HIV replication
and corresponding potential as an anti-viral drug target,
the TAR–tat complex is one of the most extensively studied
RNA–proteininteractions.EfﬁcientHIV-1replicationrequires
the interaction of the virally encoded tat protein with the TAR
Nucleic Acids Research, 2005, Vol. 33, No. 11 3449element, a short stem–loop consisting of the ﬁrst 59 nt at the
50 end of the viral RNA transcript (32–35). The apical region
of TAR (Figures 2 and 3) contains two short, A-form helical
regions (2,4,35), whose junction at a 3 nt UCU bulge serves
also as the tat binding site (32,36,37). Tat is a small basic
protein, whose size in different viral isolates varies from 86
to 101 residues (38), the ﬁrst 72 of which are required for
transactivational activity(39). In the absence oftat, production
of full-length RNA transcripts is severely attenuated. Binding
of tat to the TAR motif during transcription is associated with
dramatically increased production of full-length viral RNA
transcripts (32–34). While structures of tat or tat peptides in
complex with TAR have not yet been determined, X-ray and
high-resolution NMR studies have been able to obtain local
RNA conformations at the binding interface and have shown
binding of tat peptides and argininimide to produce signiﬁcant
structural alterations in TAR.
In unbound TAR, the presence of the bulge nucleotides
generates a distortion of the RNA at the junction of the
upper and lower helices: solution NMR studies ﬁnd the
unpaired bases U23 and C24 to be stacked continuously
above A22 (2,4). This disturbance to the helix is accommod-
ated by a looping out of U25 and a widening of the major
groove (4,40), and results in an approximately 50  average
bend in the inter-helical angle (Figure 3A) (4,9,41–43).
Solution NMR, CD and transient electric birefringence
experiments indicate that tat binding straightens and stabilizes
TAR (3,4,6,12,42,44). Binding of tat to the RNA has been
shown to be mediated by a short arginine-rich region
(49RKKRRQRRR57), which provides direct contacts with
the TAR bulge binding site (33,34,36,37). Previous work
has shown that RNA structural requirements for TAR binding
by tat-derived peptides spanning this basic binding region, or
by argininimide alone, mirror the requirements seen for bind-
ing and transactivation by the intact tat protein, suggesting that
binding of peptides or argininimide induces a conformational
change at the TAR bulge very similar to that generated by
binding of the full protein (18,32–34,36,37,40,45–52).
Accommodation of the three unpaired bulge residues
is accomplished by different means in the tat-bound RNA
(Figure 3B and D). Binding is accompanied by unstacking
of U23 and C24 and looping out of the three bulge nucleotides,
allowing the upper and lower helices surrounding the bulge to
stack coaxially, TAR to straighten and an arginine binding
pocket to form (2–4,6,12,18,42,52). Modeling based on
high-resolution NMR and chemical modiﬁcation studies sug-
gests that this TAR conformational change is initiated by the
insertion of tat or argininimide guanidinium groups into the
RNA major groove, resulting in a reorganization of key func-
tional groups at the binding interface (2–4,18,40,52,53).
U23 2F
2F
Figure 3. (A and B) Conformational changes in TAR upon tat peptide binding. The phosphate backbone is represented by yellow ribbons, highlighting rearrange-
mentsofthebulgeresiduesgeneratedbypeptidebinding.Bluespheresdenote
19FU23andpSA27labelpositionsusedinthepresentwork.Illustrationsanddistances
shownareadaptedfromsolutionNMR-derivedmodelsofthefreeandpeptide-boundRNA(5,21).(A)Unboundconformation(PDB#1ANR,modelone).(B)Bound
conformation (PDB #1ARJ, model one.) Tat residue arg52, which provides key contacts with the RNA, is shown in orange. The RNA has straightened from the
unbound conformation, residues C24 and U25 are looped out of the helix, and residue U23 has shifted to a new position adjacent to G26 and A27. (C and D)
Rearrangements at TAR bulge binding site upon tat peptide binding. Blue spheres again denote
19F U23 and pS A27 label sites. (C) Close-up of unbound
conformation, showing relative positions of U23, A27 and U38, and the inter-label separation monitored in the present study (PDB #1ANR, model one;
19F-pS inter-label separation is 12.3 A ˚ in this model). (D) Close-up of bound conformation. Tat residue arg52 is shown in green. TAR accommodation of the
tat peptide results in a significant repositioning of U23, drawing it into close proximity to A27 and U38, accompanied by a large decrease in separation between the
19F U23 and pS A27 label positions (PDB #1ARJ, model one.) Following binding, the
19F–pS distance has decreased to 5.3 A ˚ in the model shown.
3450 Nucleic Acids Research, 2005, Vol. 33, No. 11In particular, binding has been shown to be accompanied
by a marked shift in position of bulge residue U23, situating
it adjacent to G26 and A27, possibly as part of a U23:A27:U38
base triple (Figure 3D) (2–6,52,54). It has also been shown by
EPR spectroscopy that the mobility of U23 and U38 is dra-
matically reduced upon peptide binding, consistent with the
role of these nucleotides in complex formation (11,13). These
rearrangements, most notably the large change in position
undergone by bulge residue U23, suggest several suitable
diagnostic labeling sites for SSNMR observation of complex
formation.
31P–
19F REDOR solid-state NMR measurements
To monitor conformational changes accompanying the forma-
tion of the RNA–peptide complex in the solid-state sample, we
selected a label pair positioned astride the bulge region, whose
separation within TAR was shown by earlier solution NMR
studies to undergo a sizeable change upon complex formation
(Figure 3C and D). We performed
31P–
19F REDOR distance
measurements on samples of a 29-residue TAR construct, in
which 20 ﬂuorine and phosphorothioate labels were introduced
at U23 and 50 of A27, respectively, and in which the wild-type
CUGGGA upper loop was replaced with a stabilizing GAAA
tetraloop (Figure 2). This labeling choice offers several bene-
ﬁts. Recent high-resolution NMR studies of the structural
effects of phosphorothioate substitutions in an RNA hairpin
and in DNA/RNA duplexes found little or no change in con-
formation when pS labels were introduced in helical regions,
as is the case for A27 in the TAR construct used in the present
work (55–57). Furthermore, 20F sugar moiety labeling pro-
vides a structural reporter more directly sensitive to backbone
conformational changes than would be available through
a base-labeling approach. A gel mobility-shift binding assay
comparing (20F U23, pS A27) TAR and the correspond-
ing unlabeled wild-type TAR 29mer showed that both TAR
constructs bind the tat 11mer with similar afﬁnities (data not
shown.)
Unbound TAR. Representative
31P reference (S0) spectra
corresponding to the initial REDOR S/S0 point for the
unbound and bound TAR RNA are shown in Figure 4. The
phosphorothioate and backbone phosphate peaks show
approximate linewidths of 9 and 6 ppm, respectively. In
the free RNA, best ﬁts to the REDOR data showed the meas-
ured
20FU23-pS A27 inter-label distance to be 10.3 – 0.6 A ˚
(Figure 5). This result is consistent with previously reported
solution NMR results for two similar unbound HIV-1
TAR constructs (4). In that work, Aboul-ela and co-workers
used solution NMR-derived constraints to generate energy-
minimized model structures for the TAR apical region,
using samples of the 29 nt RNA construct 50-GGCAGAUCU-
GAGCCUGGGAGCUCUCUGCC-30 and a related 27mer, in
which the CUGGGA loop had been replaced by a UUCG
tetraloop. In the 20 published models (PDB #1ANR), the
mean inter-label separation corresponding to our label posi-
tions was 11.1 A ˚, while the separation itself ranged from 8.1 to
14.2 A ˚ (SD 1.7 A ˚.) The distance observed in the lyophilized
sample is thus in statistical agreement with the distance
obtained for comparable TAR constructs in solution. While
it is clearly not possible to exclude the possibility that
multiple conformers are present in the sample without further
experiments, the monotonic dephasing seen in the REDOR
data is consistent with the presence of a unique distance,
hence it is likely that the lyophilized sample contains predom-
inantly a single conformer of the unbound RNA.
Figure 4.
31PMASspectraoftheunbound(A)andbound(B)TARRNA.Plots
were generated without linebroadening and show reference (S0) spectra corre-
sponding to REDOR S/S0 points acquired at 1.23 ms. In each spectrum, the
phosphorothioate peak (pS A27) monitored to measure REDOR dephasing is
denotedby‘pS’;theremainingpeaksareisotropicandspinningsidebandpeaks
owing to unmodified backbone phosphates.
Figure 5. REDOR dephasing curves for unbound TAR RNA and TAR–tat
peptide complex. Diamonds mark data for the unbound RNA, and triangles
for the complex. Solid lines represent simulated dephasing corresponding to
10.3 and 6.6 A ˚, respectively. All simulations used SIMPSON, as described in
the text.
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to the undecamer tat peptide used in this study has been sug-
gested to produce a conformational change in TAR similar to
that generated by the full protein. REDOR measurements
taken following the addition of the tat peptide 47YGRKKR-
RQRRR57 indicated that the binding site in the TAR construct
had undergone a substantial rearrangement. The distance
between the
19F and
31P labels in the binding region was
observed to drop by 3.7 A ˚, from 10.3 A ˚ in the unbound
RNA to 6.6 – 0.7A ˚ following introduction of the peptide
(Figure 5). Although signal limitations prevent quantitative
treatment of phosphorothioate lineshape changes, little appar-
ent change in linewidth or chemical shift was observed fol-
lowing peptide binding. In both the unbound and bound
spectra, the phosphorothioate peak is slightly broader than
the superimposed phosphate peak produced by the remaining
28 nt of the crystalline RNA sample. The absence of
signiﬁcant changes in phosphorothioate linewidth or chemical
shift following peptide binding is consistent with previous
solution NMR studies, showing the label site to be in a relat-
ively well-deﬁned helical region in both the unbound and
bound RNAs. The dephasing data for the bound RNA suggest
that more than one distance may be present, indicative of
possible structural heterogeneity in the sample. While in the
present experiments the perturbation to the dephasing is small,
such a possibility cannot be excluded, as the effects of
lyophilization on biological samples have not as yet been
well characterized.
While earlier structural studies of TAR have shown U23 to
be repositioned signiﬁcantly as a result of complex formation,
to a new position near G26 and A27, these reports have
differed over what that position is. In structures determined
by several groups, the pyrimidine ring of bulge residue U23
was found to participate in a base triple with residues A27 and
U38 of the upper helix (2,6,52). In contrast, Aboul-ela et al.
found instead that the base was situated nearer to A26 (3). In a
set of 20 published energy-minimized model structures (PDB
#1ARJ) for the TAR apical region in complex with a peptide
containing both the tat basic binding domain and core region,
or with argininimide, and using samples of the same 29 and
27nt RNA constructs used in their subsequent study of the free
RNA, Aboul-ela and co-workers found the mean inter-label
separation corresponding to our label positions to be 4.8 A ˚,
while the separation this time ranged from 3.7 to 6.1 A ˚
(SD 0.74 A ˚). While the distance observed in the lyophilized
sample thus shows a signiﬁcant decrease with respect to the
distance seen in the free RNA, as expected, it is slightly larger
than that obtained for comparable bound TAR constructs in
solution. Although disagreement remains over the precise
placement of U23 in bound TAR, in both types of proposed
bound TAR structure U23 adopts relatively well-deﬁned posi-
tions near G26 or A27. Comparison of the solution NMR
results of Aboul-ela et al. for the free and tat-bound RNA
suggests that complex formation should result in a distance
change of at least 2.0 A ˚, and possibly considerably larger.
Coordinate ﬁles for alternate structures of the HIV-1 complex
are notavailable. Ineither case, and as we have observed in the
presentstudy,adecrease inthedistancebetweenourlabel sites
is expected, indicating that the 3.7 A ˚ distance change observed
in the REDOR measurements is consistent with the presence
of intact complex in the solid-state sample.
CONCLUSION
In summary, REDOR SSNMR measurements on lyophilized
samples of a 29-residue TAR RNA construct showed bind-
ing of a tat-derived peptide to result in a 3.7 A ˚ decrease in the
separation between 31P and 19F labels introduced at the bind-
ing site, from 10.3 A ˚ in the free RNA to 6.6 A ˚ in the bound
RNA. The results of previous structural studies of the free
HIV-1 TAR and of tat peptide–TAR complexes obtained
using solution NMR are supported by our data, which indicate
that a sizeable rearrangement occurred at the TAR RNA bind-
ing site following peptide addition, consistent with the pres-
ence of the peptide–TAR complex in the solid-state sample.
To ourknowledge,theseexperimentsprovidetheﬁrstexample
of an SSNMR distance measurement in an RNA–peptide
complex. SSNMR studies of the structure and dynamics of
the TAR–tat system are under way and will be reported in due
course.
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